Effect of Ketamine and Etomidate During RSI on Long Term Outcomes
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Aurora, Birmingham, Denver, Minneapolis, Nashville, and Winston-Salem, United StatesSee the 6 sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 1,756 people, planned
- Started
- 6 Apr 2022
- Expected to end
- Mar 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Ketamine
- Etomidate
- Record updated
- 20 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Enrolled in RSI trial (NCT05277896)
Who cannot take part
- Aphasic or non-verbal prior to tracheal intubation
- Cannot follow commands prior to tracheal intubation
- Non-English speaking
- Deaf
Where in United States
- University of Colorado DenverAurora, United StatesEnrolling by invitation
- University of Alabama HospitalBirmingham, United StatesEnrolling by invitation
- Denver Health Medical CenterDenver, United StatesEnrolling by invitation
- Hennepin County Medical CenterMinneapolis, United StatesEnrolling by invitation
- Vanderbilt University Medical CenterNashville, United StatesEnrolling by invitation
- Wake Forest Baptist Medical CenterWinston-Salem, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). One-third of adults who are intubated in the ED or ICU experience symptoms of posttraumatic stress disorder (PTSD). PTSD is a psychiatric disorder triggered by a "shocking, scary, or dangerous event." Critical illness, tracheal intubation, and mechanical ventilation can be traumatic and distressing events. Patients may recall the intubation procedure, the feeling of the breathing tube in their throat, or being unable to move ("paralyzed"). While on the breathing machine, patients may experience delirium, frightening hallucinations, and delusions. Patients with PTSD after critical illness can be hypervigilant, anxious, and troubled by intrusive thoughts, nightmares, and flashbacks that last months to years after critical illness and that PTSD negatively impacts patients' marriages, work, and quality of life and increases patients' risk of depression, anxiety, substance use disorder, and suicide. Ketamine may prevent PTSD symptoms by blocking the pathways in the brain's glutaminergic system that are responsible for the formation of traumatic memories In outpatients with chronic PTSD, a single dose of ketamine has been shown to reduce PTSD symptoms for up to 2 weeks. Even a modest reduction in PTSD would translate into tens of thousands of fewer cases of PTSD each year, more cases of PTSD each year than any other medical intervention evaluated to date.
The 2 groups in the trial
- Comparator: Ketamine Group
Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation.
Treatment: Ketamine
- Comparator: Etomidate Group
Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation.
Treatment: Etomidate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Ketamine and Etomidate During Rapid Sequence Intubation on Long- Term Outcomes (Long-Term Outcomes of the RSI Trial)
- Publications
- Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.Clinical pharmacology and therapeutics, 2025
- Record updated
- 20 August 2026